Pacira BioSciences, Inc. (PCRX)
Cash conversion cycle
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Days of inventory on hand (DOH) | days | 229.71 | 184.59 | 170.00 | 166.86 | 191.41 | 177.13 | 160.27 | 159.90 | 175.94 | 200.31 | 228.95 | 260.98 | 256.47 | 179.66 | 180.62 | 198.25 | 201.12 | 219.58 | 229.11 | 199.54 |
| Days of sales outstanding (DSO) | days | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Number of days of payables | days | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash conversion cycle | days | 229.71 | 184.59 | 170.00 | 166.86 | 191.41 | 177.13 | 160.27 | 159.90 | 175.94 | 200.31 | 228.95 | 260.98 | 256.47 | 179.66 | 180.62 | 198.25 | 201.12 | 219.58 | 229.11 | 199.54 |
December 31, 2024 calculation
Cash conversion cycle = DOH + DSO – Number of days of payables
= 229.71 + — – —
= 229.71
The cash conversion cycle for Pacira BioSciences, Inc. shows fluctuation over the periods provided in the data. It indicates the time taken by the company to convert its investments in inventory and other resources into cash from sales. A shorter cash conversion cycle is generally preferred as it signifies efficient management of working capital.
Analyzing the data, the cash conversion cycle ranged from a low of 159.90 days on March 31, 2023, to a high of 260.98 days on March 31, 2022. It decreased significantly from the first quarter of 2022 to the first quarter of 2023, suggesting improvements in inventory management and collection of receivables during that period.
Overall, the company experienced fluctuations in its cash conversion cycle, indicating varying efficiency in managing its working capital during the different quarters. Further analysis and comparison with industry benchmarks may provide insights into the company's operational effectiveness and financial health.
Peer comparison
Dec 31, 2024